ArticleAmerican journal of translational research2021
Platelet immunology of patients with hemophilia.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets are important in hemostasis and participate widely in metabolism. Glycoproteins (GPs) on the surface of platelets can fold into different spatial structures caused by single-nucleotide polymorphisms (SNPs) and perform as antigens. Human platelet antigen (HPAs) immunology has been reported to have a close relationship with many clinical issues, suggesting the importance of HPA genotyping and platelet antibody detection. In this study, we aimed to detect human platelet antigen (HPA) and HPA antibody characters of hemophilia patients in Hanchuan, China. Totally, 127 hemophilia A (HA) and 33 hemophilia B (HB) patients were included in this study. We examined the HPA genotypes of hemophilia patients by PCR with specific primers (PCR-SP). Then we calculated the frequencies of HPA alleles in hemophilia patients using the gene-counting method and compared them with data from normal people in China. The results showed no significant differences except that the prevalence of HPA-2b was significantly higher in HA patients when compared to healthy people (0.0827 vs. 0.0485, P=0.0212) and the prevalence of HPA-4b was significantly higher in HB patients when compared to both HA patients (0.0758 vs. 0.0079, P=0.0008) and healthy people (0.0758 vs. 0.0045, P<0.0001). Finally, using Luminex assay, we detected the features of HPA antibody in hemophilia patients and found ratios of anti-HPA-3a (7.87% in HA patients, 9.09% in HB patients, and 1.26% in healthy people), anti-HPA-5b (3.15% in HA patients, 3.03% in HB patients, and 0.42% in healthy people), and anti-HPA-2b (3.15% in HA patients, 3.03% in HB patients, and 0.21% in healthy people) were all higher in hemophilia patients. To conclude, our data indicate that the detection and identification of clinically relevant platelet antibodies are important for patients with hemophilia to prevent immune-mediated thrombocytopenia.
Indexed as
Identifiers
34540118PMC8430101W3200565878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.